Aims: In patients with atrial fibrillation, a relevant stroke risk (CHA 2 DS 2 absolute contraindication for oral anticoagulation, catheter-based LAA occlusion is performed increasingly in Europe. The present article summarises the rationale, clinical data, devices, implantation techniques and follow-up drug regimens.
Introduction cause of severe strokes, in particular in the elderly. Chronic antico-60-70%; however, it is associated with a significant annual risk of major bleedings, particularly in the elderly (Figure 1) 1 . To assess the risk of bleeding with anticoagulation the HAS-BLED score has been developed based on a real-world patient cohort treated with warfarin from the EuroHeart Survey on Atrial Fibrillation 2 . Of note, the persistent use of anticoagulation with warfarin has been observed to be below 50% even in patients after an ischaemic stroke. This is probalso by the general limitations of drug compliance 3 .
Rationale for left atrial appendage (LAA) closure in atrial fibrillation
In patients with "non-valvular atrial fibrillation" (no mitral stenoin the LAA 4 . This has stimulated development of catheter-based approaches to LAA occlusion for stroke prevention 5 , an approach that has a lower risk of major bleedings as compared to chronic anticoagulation and is not dependent on drug compliance. Moreover, recent data suggest that for patients with CHA 2 DS 2 pulmonary vein isolation may not eliminate the need for stroke prevention by anticoagulation or other approaches 6 . Currently, one randomised, multicentre study has been completed comparing the safety and efficacy of LAA occlusion to warfarin AF trial 7 . In this study, patients were randomised to either LAA take warfarin for 45 days, then switched to dual platelet inhibition At 1,065 patient-years follow-up, the probability of non-inferiority primary efficacy endpoint, defined as a primary composite endpoint of stroke, cardiovascular death, and systemic embolism 7 . Safety events were more common in the device intervention group -dural complications, including pericardial tamponade 7 . After trial from 1,002 patients demonstrated a significant decline in the rate of procedure-or device-related safety events with increasing operator 8 . Subgroup analysis -cacy of the procedure in this patient subgroup, in whom the bleeding risk as well as the thromboembolic risk are increased . mortality in patients assigned to WATCHMAN device treatment which was accompanied by reductions in haemorrhagic stroke -sion with the WATCHMAN device showed favourable changes in -10 . Early in 2014, these data led to a favourable vote of an FDA panel on the indication for a WATCHMAN LAA AF. Already in 2012 European Society of Cardiology guidelines gave a class IIb indication for LAA occlusion in patients with a relevant stroke risk who are not eligible for long-term anticoagulation.
RISK OF MAJOR BLEEDING WITH NOVEL ORAL ANTICOAGULANTS (NOACS)
low-risk patients (Figure 1) 
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ROCKET-AF ARISTOTLE AVERROES CHADS 2 2.1 3.4 2.1 2.1 HAS-BLED n/a n/a 2.0 n/a . The published data regarding bleeding risk associated with warfarin and NOACs are summarised in Figure 1 . In summary, both warfarin as well as NOACs should be used with caution in elderly patients with increased bleeding risk. Alternatives for stroke prevention are needed. Figure 2 suggests a potential algorithm for patient selection for LAA closure based on the above-mentioned data regarding safety the risk of bleeding with chronic anticoagulation. In particular, LAA occlusion can be considered for those patients with a relevant risk of stroke (as defined by the CHA 2 DS 2 -nificantly increased risk of major bleedings (such as in patients with
PATIENT SELECTION FOR LAA CLOSURE

Devices in clinical development for LAA occlusion
There are several devices in clinical development for catheter-based LAA occlusion. The most commonly used devices in Europe at present
WATCHMAN LAA OCCLUSION DEVICE
The WATCHMAN device ( Figure 3A ) AF study. Oversizing of the device by 15-30% rather than the Atrial fibrillation (non-valvular) CHA 2 DS 2 -VASc >1 Figure 3C ) 21 . It has several modifications including a larger LAA orifice disc, a low-profile end screw and a longer lobe length to improve sealing performance and further reduce the risk of complications 21 . The low-profile end screw may facilitate endothelialisation of the device with the aim of reducing the risk of device-associated thrombi 22 . The company (St. --tres in Canada and Europe. The redesigned ACP2/Amulet device will be introduced into the market in the second half of 2014. human studies are ongoing to receive CE mark in 2014.
TRANSCATHETER PATCH OCCLUSION (SIDERIS DEVICE)
This is a bioabsorbable approach to LAA occlusion ( Figure 3G ). The transcatheter patch is positioned in the LAA and "released" by distally activating the surgical adhesive by direct injection of alka-26 . This frameless, balloon-deliverable device has been used before for occlusion of heart defects. The patches are tailored from polyurethane foam and delivered using a supportive balloon 26 . The supportive balloon catheter is removed 45 min after surgical adhesive activation.
Figure 3. Catheter-based LAA occluders in clinical development. A) WATCHMAN occluder (in clinical use, endpoint studies available: PROTECT AF, CAP registry, PREVAIL, ASAP, ALSTER-LAA). B) AMPLATZER Cardiac Plug (in clinical use, registry data available, large clinical endpoint study initiated). C) AMPLATZER "Amulet" (CE mark available, currently in revision for delivery system). D) Coherex WaveCrest (CE mark in 2013). E) SentreHeart transcutaneous ligation (CE mark, in use in the USA). F) Occlutech LAA occluder. G) Transcatheter patch: bioresorbable, frameless LAA occlusion. H) "LAmbre" device consisting of a fabric-enriched cover and an umbrella connected by a short central waist.
A clinical registry of 20 patients has been reported in 2011, in which 17 patients underwent successful LAA closure. In three patients, the device was retrieved because the patch did not attach 26 .
LIFETECH LAMBRE DEVICE
The name "LAmbre" is derived from "an umbrella in the left atrial a fabric-enriched cover and an umbrella connected by a short central waist ( Figure 3H ) 27 . The device is delivered by an 8-10 Fr sheath 27 .
have been reported so far for this LAA occlusion device.
Insights into procedural optimisation of catheter-based LAA occlusion
Independent of the particular LAA occlusion device used, many procedural steps are similar. Here we focus in particular on aspects to optimise procedural success.
TRANSSEPTAL PUNCTURE SITE
The location of the transseptal puncture is key for an optimal access to the LAA and delivery of the LAA closure device. As the LAA is mostly located in an anterior and superior position, an inferior -quently facilitates the access to the LAA and allows for an optimal perpendicular positioning, i.e., of the WATCHMAN or ACP device in the neck and body of the LAA (Figure 4A) . A high and/or anterior transseptal puncture will often result in a suboptimal positioning of the delivery catheter in the LAA (Figure 4A) . Most centres choose a high transseptal puncture for LAA occlusion only in the rare cases in
DELIVERY SHEATH POSITIONING VIA STIFF WIRE
Following transseptal puncture, a pigtail catheter is usually positioned in the LA using a soft wire. After LAA angiography, the delivery sheath is delivered to the left atrium via a stiff wire (e.g., Amplatz Super Stiff with the wire in the LAA, very particular care is needed to avoid periprocedural cardiac effusion, given the thin wall of the LAA 8 . The use of a pigtail catheter in the delivery sheath will help to avoid cardiac -ple for the WATCHMAN implantation. Manipulating a pigtail catheter in the LAA was found to be safe by many operators (Figure 4B ).
MEASURES TO AVOID AIR EMBOLISM
Air embolisation was a relevant problem in the beginning of catheter-based LAA closure; however, this has been markedly reduced be taken to avoid air bubbles while loading the device into the delivabove 5-10 mmHg by sufficient hydration of the patient, if possible. 
IMAGING AND MEASUREMENT OF LAA SIZE
An appropriate measurement of the LAA landing zone is critical to avoid undersizing or oversizing of the device. This is frequently visualises the largest ostial LAA diameter and distal LAA part; it is the standard angulation for releasing the WATCHMAN device. AnWaveCrest device implantation ( Figure 5A) .
The decision on device size should be based on measurements of the LAA ostium/landing zone which is marked inferiorly by the cirto the delivery catheter. Generally 15-30% compression is recommended to achieve optimal results with the WATCHMAN device. To prevent acute or subacute pericardial effusion, the sheath and device are only moved backwards once the pigtail catheter serving as rail for the sheath has been removed. The positioning of the delivery catheter to the upper anterior lobe results in a good WATCHMAN position after release ( Figure 5B ) an inferior device protrusion. After positioning of the WATCHMAN If these criteria are met, the device can be released ( Figure 5C ). After positioning of the ACP device, the following parameters are checked:
test to confirm stability of the device.
PREVENTION AND HANDLING OF COMPLICATIONS
As the delivery sheath is soft, heavy compression of the vein and/or iliac kinking may pose a problem for device delivery. A larger, stiffer delivered to the right atrium. Thrombus formation at the device or sheath during the procedure may occur if the ACT falls below the recommended 200 sec. ACT should therefore be checked carefully.
Pericardial effusion may occur following LAA occlusion either manipulation within the LAA, device recapture and repositioning, device, i.e., by accidental release of the device in a small distal lobe increase the risk of pericardial effusion. Frequently, pericardiocentesis with or without reversal of heparin is sufficient to control thrombus formation in the pericardial space limiting the possibility of drainage; therefore protamine needs to be used with caution.
Follow-up and medical therapy after catheterbased LAA occlusion for thrombus formation on the device during the 3-6 months of -ally performed between 45 days and three months after the proce--at the device 7 . The multicentre ASAP study as well as the single---bition was found to be equally effective in preventing thrombus formation as compared to warfarin . Dual antiplatelet therapy is usually stopped in patients after 3-6 months, depending on the follow-up findings at three months in most centres. Thereafter, patients are currently mainly treated with low-dose aspirin. Whether patients without coronary heart disease or other manifestations of arteriosclerosis should completely stop antithrombotic therapy needs to be studied in future trials.
Summary and conclusion
Accumulating data suggest that catheter-based occlusion of the LAA is an effective and safe measure for stroke prevention in patients with AF. Data obtained with the WATCHMAN device suggest that this procedure is non-inferior to oral anticoagulation with warfarin. After had an improved overall mortality and quality of life. In patients with previous gastrointestinal or intracerebral bleeding, caution with anticoagulation has been recommended, and LAA occlusion may represent a viable alternative for these patients [28] [29] [30] . Periprocedural events --clinical studies is available for the WATCHMAN device. For the WaveCrest device has now become available in Europe. There are several novel devices for LAA occlusion in early clinical develop--tarium" for this procedure in the near future.
Impact on daily practice
Atrial fibrillation is a highly frequent cause of stroke and the persistent use of anticoagulation for stroke prevention is observed intensely developed as a novel approach for stroke prevention in patients with non-valvular atrial fibrillation, in part based on the appendage in patients with atrial fibrillation. It is thought that LAA closure can be particularly considered in patients with a relevant ischaemic risk and an elevated bleeding risk.
